Loading…

Favorable efficacy of S‐1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region

Cutaneous squamous cell carcinoma is usually treated with surgery; however, locoregionally advanced cutaneous squamous cell carcinoma can be difficult to resect. Although recent guidelines from Western countries recommend using anti–programmed cell death protein 1 (PD‐1) antibodies, including cemipl...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2024-02, Vol.51 (2), p.271-279
Main Authors: Izumi, Teruaki, Teramoto, Yukiko, Kamimura, Anna, Doi, Reiichi, Takai, Sayaka, Mori, Tatsuhiko, Koizumi, Shigeru, Kawahara, Yu, Aitake, Urara, Lei, Xiaofeng, Inomata, Naoko, Inafuku, Kazuhiro, Nakamura, Yasuhiro
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous squamous cell carcinoma is usually treated with surgery; however, locoregionally advanced cutaneous squamous cell carcinoma can be difficult to resect. Although recent guidelines from Western countries recommend using anti–programmed cell death protein 1 (PD‐1) antibodies, including cemiplimab and pembrolizumab, there are no approved anti–PD‐1 antibodies for locoregional cutaneous squamous cell carcinoma in Asian countries. S‐1 is an oral drug with a low incidence of severe toxicity that can be used for head and neck cancers, including head and neck locoregional cutaneous squamous cell carcinoma, in Japan. We retrospectively evaluated patients with head and neck locoregional cutaneous squamous cell carcinoma treated with S‐1 at two Japanese institutions (2008–2022). The initial dosage was determined by the body surface area (
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.17057